Literature DB >> 8481920

Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice.

S W McLeskey1, J Kurebayashi, S F Honig, J Zwiebel, M E Lippman, R B Dickson, F G Kern.   

Abstract

Successful antiestrogen treatment in patients with tamoxifen-responsive breast tumors is often followed by an outgrowth of tumors cells that are antiestrogen resistant, implying that estrogen-dependent tumors can become estrogen-independent. In an effect to mimic this progression, we have transfected fibroblast growth factor 4 into MCF-7 cells, a human breast carcinoma cell line that is estrogen-dependent for growth in nude mice. This transfection results in cell lines that form progressively growing, metastatic tumors when injected s.c. into untreated or tamoxifen-treated ovariectomized nude mice. In contrast to the parental cell line, growth of transfected cells in ovariectomized nude mice is stimulated by tamoxifen treatment and inhibited by estrogen treatment of the mice. Parental MCF-7 cells were transfected with an expression vector for beta-galactosidase, conferring the ability to convert the chromogenic substrate, 5-bromo-4-chloro-3-indoyl-beta-galactoside, to a blue color and allowing the detection of their presence within tumors developing after coinoculation with fibroblast growth factor 4-transfected cells. The fibroblast growth factor 4-transfected cells could support growth and metastasis of the beta-galactosidase-expressing parental cell line when both lines were coinjected into the same site in untreated or tamoxifen-treated, ovariectomized mice. These data suggest a possible role for fibroblast growth factors in the progression of breast tumors to an estrogen-independent, antiestrogen-resistant, metastatic phenotype. They also support a role for paracrine factors in mixed populations of tumor cells of differing states of malignant progression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8481920

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment.

Authors:  A J Hayes; L Y Li; M E Lippman
Journal:  BMJ       Date:  1999-03-27

2.  Angiogenesis Inhibitor O-(Chloroacetyl-carbamoyl) fumagillol (TNP-470) Inhibits Tumor Angiogenesis, Growth and Spontaneous Metastasis of MKL-4 Human Breast Cancer Cells in Female Athymic Nude Mice.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

3.  Quantification of fibronectin matrix assembly sites using a novel ELISA assay.

Authors:  Mingzhe Zheng; Anthony Ambesi; Lin Yu; Paula J McKeown-Longo
Journal:  Matrix Biol       Date:  2006-12-29       Impact factor: 11.583

4.  Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling.

Authors:  Christine M Fillmore; Piyush B Gupta; Jenny A Rudnick; Silvia Caballero; Patricia J Keller; Eric S Lander; Charlotte Kuperwasser
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

5.  In Vivo Monitoring of Multiple Circulating Cell Populations Using Two-photon Flow Cytometry.

Authors:  Eric R Tkaczyk; Cheng Frank Zhong; Jing Yong Ye; Andrzej Myc; Thommey Thomas; Zhengyi Cao; Raimon Duran-Struuck; Kathryn E Luker; Gary D Luker; Theodore B Norris; James R Baker
Journal:  Opt Commun       Date:  2008-02-15       Impact factor: 2.310

6.  Anti-vascular therapy: a new approach to cancer treatment.

Authors:  A J Hayes; L Y Li; M E Lippman
Journal:  West J Med       Date:  2000-01

Review 7.  The role of angiogenic growth factors in breast cancer progression.

Authors:  F G Kern; M E Lippman
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

8.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

Review 9.  Molecular biology of breast carcinoma.

Authors:  D el-Ashry; M E Lippman
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

10.  Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors.

Authors:  Zhican Qu; Sabrina Van Ginkel; Anshu M Roy; Louise Westbrook; Mubina Nasrin; Yulia Maxuitenko; Andra R Frost; Delicia Carey; Wenquan Wang; Rongbao Li; William E Grizzle; Jaideep V Thottassery; Francis G Kern
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.